Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

SAN DIEGO, Nov. 7, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the third quarter of 2011 and discussed recent business progress.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The past few months highlight the progress at Halozyme on all fronts, with positive results from our Insulin programs, Roche's Herceptin SC Phase 3 study and additional regulatory submissions for Baxter's HyQ program," said Gregory I. Frost, Ph.D., Halozyme's President and CEO. "The initiation of trials with PEGPH20 and HTI-501, two first in class biologics developed by Halozyme, further support our growth strategy balanced by partnered revenue."

Recent Highlights

  • Announced positive results from the Phase 3 HannaH trial, conducted by Roche, showing that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), demonstrated comparable efficacy to Herceptin given as an intravenous (IV) infusion. HannaH is a Phase 3, open-label trial involving 596 women with HER2-positive early breast cancer and was designed to compare trastuzumab concentration in the blood, efficacy and safety of Herceptin SC to that of Herceptin IV. The trial met its co-primary PK and efficacy endpoints of pathologic complete response and trastuzumab concentration in the blood (serum concentrations) and efficacy.  No new side effects were seen compared to previous trials with Herceptin IV.
  • Presented positive results from
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... -- Custom Computer Specialists, Inc. ("Custom"), a leading healthcare IT ... of the Primary Care Development Corporation,s ("PCDC") Corporate Circle. ... support of PCDC,s mission to expand access to primary ... in 1993, PCDC has been a key force of ... over 100 completed primary care projects, valued at over ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
    (Date:6/29/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, ... that a collaboration led by the Icahn School of ... the first comprehensive analysis of a diploid human genome ... and genome mapping. This study, published today in ... contiguous diploid human genome assembly obtained without using inference-based ...
    (Date:6/29/2015)... MO (PRWEB) , ... June 29, 2015 , ... The ... – July 16 and for the fourth year in a row, will bring top ... changes are taking place at the intersection of data and technology. The event is ...
    Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3
    ... , , , , ... MON ) R&D pipeline is on the verge of ... improved yield for growers and has the company poised to meet ... executive officer and president, will tell investors today. , , ...
    ... August 13 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader in the field ... of 2009. , , Highlights, - ... in Canada following two previous clinical trials, - ... a clinically important health benefit, accomplished by a significant, ...
    ... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... its financial results for the second quarter ended June 30, ... pleased to report in April that the FDA accepted Auxilium,s ... Dupuytren,s disease and we are looking forward to the Arthritis ...
    Cached Biology Technology:Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7Amsterdam Molecular Therapeutics Reports Half Year Results 2009 2Amsterdam Molecular Therapeutics Reports Half Year Results 2009 3Amsterdam Molecular Therapeutics Reports Half Year Results 2009 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6
    (Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
    (Date:6/18/2015)... -- This report analyzes the worldwide markets for Immunoassay ... which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay Systems, ... and Nephelometric Immunoassay Systems. The report provides separate comprehensive ... Japan , Europe ... America , and Rest of World. Annual estimates ...
    (Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
    Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
    ... as the 2007 winner of the ALPSP/Charlesworth Award for ... a significantly innovative approach to any aspect of scholarly ... years award was RSC Project Prospect from the Royal ... semantics into chemical science publishing. RSC Project Prospect journals ...
    ... of HIV research through his rational approach to trying to ... method is based on gaining an understanding of the molecular ... sites on the virus that the antibodies target a ... molecules used in an HIV-1 vaccine. He has published ...
    ... Washington, DC September 13, 2007 One of the 2007 ... sponsored by ASM will be presented to Hung Ton-That, ... and Structural Biology, University of Connecticut Health Center. ... in microbiology and infectious disease. Dr. Ton-Thats ...
    Cached Biology News:RSC Project Prospect scoops prestigious award 2
    ...
    Request Info...
    ... Cultrex High Protein Concentration Basement Membrane ... use in in vivo applications where ... times, increased gel strength, and elevated ... has the advantage of lot-to-lot consistency ...
    mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
    Biology Products: